{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:06:07Z","timestamp":1793016367927,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004065.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000}}],"reference-count":354,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004065.pub4","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T10:47:47Z","timestamp":1689850067000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Medical treatment of eosinophilic esophagitis"],"prefix":"10.1002","volume":"2023","author":[{"given":"James P","family":"Franciosi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition; Nemours Children's Hospital; Orlando FL USA"},{"name":"College of Medicine; University of Central Florida; Orlando USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Gordon","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Sinopoulou","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S","family":"Dellon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing; University of North Carolina School of Medicine; Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition; University of Illinois College of Medicine at Peoria and Children's Hospital of Illinois; Peoria IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing; University of North Carolina School of Medicine; Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Guti\u00e9rrez-Junquera","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology; University Hospital Puerta de Hierro Majadahonda. Autonomous University of Madrid; Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajitha D","family":"Venkatesh","sequence":"additional","affiliation":[{"name":"Pediatrics, Gastroenterology & Hepatology & Nutrition; Nationwide Children's Hospital; Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Erwin","sequence":"additional","affiliation":[{"name":"Pediatric Allergy; Nationwide Children's Hospital; Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Egiz","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assem","family":"Elleithy","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B","family":"Mougey","sequence":"additional","affiliation":[{"name":"Clinical Pharmacogenomics and Translational Research; Nemours Children's Health System; Jacksonville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"10.1002\/14651858.CD004065.pub4-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1038\/ajg.2010.320-1","article-title":"A randomized placebo-controlled trial of swallowed fluticasone as treatment of eosinophilic esophagitis 2010 ACG auxiliary award","volume":"105 Suppl 1","author":"Alexander","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD004065.pub4-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.cgh.2012.03.018","article-title":"Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis","volume":"10","author":"Alexander","year":"2012","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0003|cit3","unstructured":"Topical steroid treatment for eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00275561"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0016-5085(16)30190-1","article-title":"A randomized placebo-controlled trial of montelukast in maintenance treatment of eosinophilic esophagitis","volume":"150","author":"Alexander","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cgh.2016.09.013","article-title":"Montelukast does not maintain symptom remission after topical steroid therapy for eosinophilic esophagitis","volume":"15","author":"Alexander","year":"2017","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0006|cit6","unstructured":"Trial of montelukast in eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00511316"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"AB159","DOI":"10.1016\/j.jaci.2009.12.625","article-title":"Clinical characteristics of pediatric eosinophilic esophagitis subjects with inadequate response to or intolerance of prior therapies receiving mepolizumab in a multicenter clinical trial","volume":"125","author":"Aceves","year":"2010","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0008|cit8","first-page":"S123","article-title":"Resolution of esophageal remodeling following oral viscous budesonide (OVB) therapy for eosinophilic esophagitis (EoE)","volume":"138","author":"Aceves","year":"2010","journal-title":"Gastroenterology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"AB129","DOI":"10.1016\/j.jaci.2009.12.509","article-title":"The pharmacodynamic effects of mepolizumab, a humanized monoclonal antibody against IL-5, in pediatric patients with eosinophilic esophagitis: A randomized, double-blind, controlled clinical trial","volume":"125","author":"Assa'ad","year":"2010","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa'ad","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/labinvest.2009.151","article-title":"Effect of a monoclonal antibody (mepolizumab) against lnterleukin-5 (IL-5) in reducing eosinophilic inflammation in children with eosinophilic esophagitis (EoE)","volume":"90","author":"Collins","year":"2010","journal-title":"Laboratory Investigation"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.1097\/MPG.0b013e3181c64b4a","article-title":"PK and PD of mepolizumab in pediatric subjects with eosinophilic esophagitis: A randomized, double-blind, controlled clinical trial","volume":"49 Suppl 1","author":"Gupta","year":"2009","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"AB234","DOI":"10.1016\/j.jaci.2009.12.913","article-title":"Utility of eosinophil-derived neurotoxin as a biomarker in eosinophilic esophagitis: results from a randomized, double-blind, controlled trial of mepolizumab in pediatric patients","volume":"125","author":"Gupta","year":"2010","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0014|cit14","unstructured":"Intravenous mepolizumab In children with eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00358449"},{"issue":"6","key":"10.1002\/14651858.CD004065.pub4-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jaci.2013.02.042","article-title":"Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis","volume":"131","author":"Newbury","year":"2013","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"AB202","DOI":"10.1016\/j.jaci.2011.12.180","article-title":"The effect of anti-IL-5 therapy on esophageal mastocytosis in pediatric eosinophilic esophagitis","volume":"129","author":"Otani I","year":"2012","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2500\/ar.2017.8.0202","article-title":"Effect of topical beclomethasone on inflammatory markers in adults with eosinophilic esophagitis: a pilot study","volume":"8","author":"Bhardwaj","year":"2017","journal-title":"Allergy Rhinol (Providence)"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"A19","DOI":"10.1016\/j.anai.2012.09.018","article-title":"A randomized double blind placebo controlled crossover study of the effect of swallowed beclomethasone dipropionate on inflammatory markers in adult patients with eosinophilic esophagitis: a pilot study","volume":"109","author":"Ghaffari","year":"2012","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"A99","DOI":"10.1016\/j.anai.2011.09.019","article-title":"A randomized double blind placebo controlled crossover study of the effect of swallowed beclomethasone dipropionate on inflammatory markers in adult patients with eosinophilic esophagitis:a pilot study","volume":"107","author":"Ghaffari","year":"2011","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0020|cit20","unstructured":"A randomized double blind placebo controlled study of the effect of swallowed beclomethasone dipropionate on inflammatory markers in adult patients with eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01016223"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.gastro.2014.04.019","article-title":"Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis","volume":"147","author":"Butz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0022|cit22","unstructured":"A study of Flovent in patients with eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00426283"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1053\/j.gastro.2014.05.036","article-title":"Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE","volume":"147","author":"Clayton","year":"2014","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1016\/S0016-5085%2811%2960951-7","article-title":"A pilot study of the treatment of eosinophilic esophagitis with omalizumab","volume":"140","author":"Fang","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0025|cit25","unstructured":"A pilot study of the treatment of eosinophilic esophagitis with omalizumab https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00123630"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0026|cit26","first-page":"S180","article-title":"Nebulized\/swallowed vs viscous\/swallowed budesonide for treatment of eosinophilic esophagitis: results from a randomized, open-label, clinical trial","volume":"142","author":"Dellon","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/j.gastro.2012.04.049","article-title":"Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis","volume":"143","author":"Dellon","year":"2012","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0028|cit28","first-page":"S180","article-title":"Mucosal contact time determines histologic effectiveness of oral budesonide preparations in eosinophilic esophagitis: a randomized trial using scintigraphy","volume":"142","author":"Dellon","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0029|cit29","unstructured":"Topical budesonide treatment for eosinophilic esophagitis (EoE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00961233"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1097\/MPG.0000000000002518","article-title":"Baseline characterization of adolescent and adult patients with eosinophilic esophagitis (EOE) using the eoe histology scoring system: analyses from a randomized, placebo-controlled trial","volume":"69 Suppl 2","author":"Collins","year":"2019","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"S229","DOI":"10.14309\/01.ajg.0000591100.32919.d0","article-title":"Baseline characterization of patients with eosinophilic esophagitis (EOE) using the eoe histology scoring system and correlations with endoscopic and symptom outcomes: Analyses from a randomized, placebo-controlled trial","volume":"114 Suppl","author":"Collins","year":"2019","journal-title":"American Journal of Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD004065.pub4-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1097\/PAS.0000000000001361","article-title":"Budesonide oral suspension significantly improves eosinophilic esophagitis histology scoring system results: analyses from a 12-week, phase 2, randomized, placebo-controlled trial","volume":"43","author":"Collins","year":"2019","journal-title":"American Journal of Surgical Pathology"},{"issue":"4","key":"10.1002\/14651858.CD004065.pub4-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cgh.2018.05.051","article-title":"Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis","volume":"17","author":"Dellon","year":"2019","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/S0016-5085(16)30715-6","article-title":"Safety and efficacy of oral budesonide suspension for maintenance therapy in eosinophilic esophagitis: Results from a prospective open-label study of adolescents and adults","volume":"150","author":"Dellon","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD004065.pub4-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1053\/j.gastro.2016.11.021","article-title":"Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis","volume":"152","author":"Dellon","year":"2017","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0036|cit36","first-page":"S662","article-title":"Pain with swallowing is a frequent and under-appreciated symptom in eosinophilic esophagitis: analysis from a multicenter randomized placebo-controlled trial","volume":"150","author":"Dellon","year":"2016","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/S0016-5085(15)30530-8","article-title":"Oral budesonide suspension significantly improves dysphagia and esophageal eosinophilia: results from a multicenter randomized double-blind placebo-controlled trial in adolescents and adults with eosinophilic esophagitis","volume":"148","author":"Dellon","year":"2015","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S792","DOI":"10.1016\/S0016-5085(15)32705-0","article-title":"The dysphagia symptom questionnaire is responsive and valid for measuring patient-reported outcomes in eosinophilic esophagitis: Analysis from a multicenter randomized placebo controlled trial","volume":"148","author":"Dellon","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD004065.pub4-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cgh.2020.03.060","article-title":"Improvements in dysphagia and pain with swallowing in patients with eosinophilic esophagitis receiving budesonide oral suspension","volume":"19","author":"Dellon","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"AB91","DOI":"10.1016\/j.jaci.2020.12.348","article-title":"Efficacy and safety of budesonide oral suspension in a pediatric population: pooled data from a phase 2 and phase 3 trial in patients with eosinophilic esophagitis","volume":"147","author":"Gupta","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"10","key":"10.1002\/14651858.CD004065.pub4-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1016\/j.cgh.2018.11.045","article-title":"Clinical features at baseline cannot predict symptom response to placebo in patients with eosinophilic esophagitis","volume":"17","author":"Hirano","year":"2019","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0016-5085(15)30102-5","article-title":"Randomized, double-blind, placebo controlled trial demonstrates the efficacy of oral budesonide suspension in improving endoscopically identified esophageal abnormalities in eosinophilic esophagitis","volume":"148","author":"Hirano","year":"2015","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S854","DOI":"10.1016\/S0016-5085(17)32941-4","article-title":"Clinical features at baseline are not clearly associated with symptomatic placebo response in adolescents and adults with eosinophilic esophagitis during a placebo runin period of a double-blind, randomized, controlled trial of budesonide oral suspension","volume":"152","author":"Hirano","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0044|cit44","unstructured":"OBS in adolescent and adults with EoE: a phase II, randomized, double-blind, placebo controlled, study with an open label extension https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01642212"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"S819","DOI":"10.1016\/S0016-5085(20)32728-1","article-title":"Determination of an endoscopic response threshold for the eosinophilic esophagitis endoscopic reference score: analysis of a randomized comparative clinical trial of topical steroids","volume":"158","author":"Cotton","year":"2020","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085%2820%2932729-3","article-title":"Dysphagia in eosinophilic esophagitis improves with topical steroid treatment independent of improvement in endoscopic and histologic measures of mucosal inflammation: analysis of a randomized comparative effectiveness clinical trial","volume":"158","author":"Cotton","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD004065.pub4-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/doaa003","article-title":"Utility of major basic protein, eotaxin-3, and mast cell tryptase staining for prediction of response to topical steroid treatment in eosinophilic esophagitis: analysis of a randomized, double-blind, double dummy clinical trial","volume":"33","author":"Dellon","year":"2020","journal-title":"Diseases of the Esophagus"},{"issue":"1","key":"10.1002\/14651858.CD004065.pub4-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/j.gastro.2019.03.014","article-title":"Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial","volume":"157","author":"Dellon","year":"2019","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0016-5085(19)38720-7","article-title":"Rapid recurrence of symptoms, endoscopic findings, and esophageal eosinophilia without maintenance thearpy after successful initial treatment: results from the observation phase of a randomized, double-blind, double dummy clinical trial","volume":"156","author":"Dellon","year":"2019","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"S837","DOI":"10.1016\/S0016-5085(20)32771-2","article-title":"Utility of major basic protein, eotaxin-3, and mast cell tryptase staining for prediction of response to topical steroid treatment in eosinophilic esophagitis: analysis of a randomized, double-blind, double-dummy clinical trial","volume":"158","author":"Dellon","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD004065.pub4-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.cgh.2019.08.050","article-title":"Rapid recurrence of eosinophilic esophagitis activity after successful treatment in the observation phase of a randomized, double-blind, double-dummy trial","volume":"18","author":"Dellon","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0016-5085(19)36966-5","article-title":"Oral viscous budesonide versus swallowed fluticasone inhaler for initial treatment of adolescents and adults with eosinophilic esophagitis: a randomized, double-blind, double-dummy clinical trial","volume":"156","author":"Dellon","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0053|cit53","unstructured":"Budesonide versus fluticasone for treatment of eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02019758"},{"issue":"12","key":"10.1002\/14651858.CD004065.pub4-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.14309\/ajg.0000000000000957","article-title":"Dilation modifies association between symptoms and esophageal eosinophilia in adult patients with eosinophilic esophagitis","volume":"115","author":"Safroneeva","year":"2020","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD004065.pub4-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"P1488","DOI":"10.1016\/j.cgh.2021.06.020","article-title":"Long- term treatment of eosinophilic esophagitis with budesonide oral suspension","volume":"20","author":"Dellon","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD004065.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S-247-8","DOI":"10.1016\/S0016-5085(21)01334-2","article-title":"Loss of histologic, symptom and endoscopic efficacy following treatment withdrawal in patients with eosinophilic esophagitis: a phase 3, randomized withdrawal study of budesonide oral suspension","volume":"160","author":"Dellon","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0057|cit57","unstructured":"An extension study to evaluate maintenance of efficacy and long-term treatment effect of oral budesonide suspension (OBS) in adults and adolescents with eosinophilic esophagitis (EoE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02736409"},{"issue":"Supplement","key":"10.1002\/14651858.CD004065.pub4-BIB0058|cit58","first-page":"s387","article-title":"Dupilumab improves clinical, symptomatic, histologic, and endoscopic aspects of EoE up to 24 weeks: pooled results from parts A and B of phase 3 LIBERTY-EoE-TREET","volume":"117","author":"Dellon","year":"2022","journal-title":"American Journal of Gastroenterology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"AB91","DOI":"10.1016\/j.jaci.2020.12.347","article-title":"Dupilumab improves health-related quality of life (HRQoL) and reduces symptom burden in patients with eosinophilic esophagitis (EoE): results from part A of a randomized, placebo-controlled three-part phase 3 study","volume":"147","author":"Dellon","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0060|cit60","first-page":"S","article-title":"Clinical and histological improvements with weekly dupilumab treatment in adult and adolescent patients with eosinophilic esophagitis at week 24: weekly and every 2 weeks; results from part b of the 3-part LIBERTY EoT TREET study","volume":"162","author":"Dellon","year":"2022","journal-title":"Gastroenterology"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0061|cit61","first-page":"S","article-title":"Dupilumab improves histologic and clinical aspects of disease in adult and adolescent patients with eosinophilic esophagitis at week 24: results from part b of the 3-part LIBERTY EoT TREET Study","volume":"162","author":"Dellon","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0062|cit62","first-page":"LB3","article-title":"A phase 3, randomized, 3-part study to investigate the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis: results from part A","volume":"115","author":"Dellon","year":"2020","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD004065.pub4-BIB0063|cit63","first-page":"LB10","article-title":"Dupilumab efficacy and safety up to 52 weeks in adult and adolescent patients with eosinophilic esophagitis: results from part A and C of a randomized, placebo-controlled three-part, phase 3 LIBERTY EoE TREET Study","volume":"9","author":"Dellon","year":"2021","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0064|cit64","first-page":"52","article-title":"LIBERTY EoE TREET: Results from parts A and C of the phase 3, randomized, 3-part LIBERTY EoE TREET study to investigate the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis up to 52-weeks","volume":"116","author":"Dellon","year":"2021","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0065|cit65","unstructured":"Dellon ES Rothenberg ME Collins MH Hirano I Chehade M Bredenoord AJ A phase 3, randomized, 3-part study to investigate the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis: results from part A https:\/\/www.eventscribe.com\/2020\/ACG\/fsPopup.asp?efp=RElCSUFHUk02NDI2&PresentationID=783291&rnd=0.6661928&mode=presinfo American College of Gastroenterology"},{"issue":"25","key":"10.1002\/14651858.CD004065.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0067|cit67","unstructured":"A study to determine the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis (EoE) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NCT03633617"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0068|cit68","unstructured":"Study to determine the efficacy and safety of dupilumab in adult and adolescent patients With eosinophilic esophagitis (EoE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03633617"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"S817","DOI":"10.1016\/S0016-5085(20)32722-0","article-title":"An episode-based, patient-reported outcome measure of dysphagia accurately captures response to treatment with apt-1011 in a phase 2b, randomized, double-blind, placebo-controlled, clinical trial in adults with eosinophilic esophagitis","volume":"158","author":"Dellon","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.14309\/01.ajg.0000703428.23468.41","article-title":"Safety and efficacy of long-term treatment of EoE with fluticasone propionate orally disintegrating tablet (APT-1011): results from 40 weeks treatment in a phase 2b randomized double-blind placebo-controlled trial","volume":"115 Suppl","author":"Dellon","year":"2020","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD004065.pub4-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1177\/2050640619888859","article-title":"Safety and efficacy of 4 dosage regimens of APT-1011: results from a phase 2B randomized double-blind placebo-controlled trial to select the best dosage regimen for further development","volume":"7","author":"Dellon","year":"2019","journal-title":"United European Gastroenterology Journal"},{"issue":"11","key":"10.1002\/14651858.CD004065.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"2485-2494.e15","DOI":"10.1016\/j.cgh.2022.02.013","article-title":"Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: randomized Controlled Trial","volume":"20","author":"Dellon","year":"2022","journal-title":"Clinical gastroenterology and hepatology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0073|cit73","unstructured":"Dellon ES Lucendo AJ Schlag C Schoepfer AM Falk GW Eagle G Fluticasone propionate orally disintegrating tablet (APT-1011) for eosinophilic esophagitis: randomized controlled trial Clinical Gastroenterology and Hepatology S1542 10.1016\/j.cgh.2022.02.013 35181572"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0074|cit74","unstructured":"Study in subjects with eosinophilic esophagitis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2016-004749-10-BE"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0075|cit75","unstructured":"Efficacy, safety, and pharmacokinetics of APT-1011 in subjects with eosinophilic esophagitis (EoE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03633617"},{"issue":"Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.14309\/01.ajg.0000774304.21136.36","article-title":"Patient-reported symptom improvement following treatment with APT-1011 in patients with eosinophilic esophagitis as measured by the prose: results from flute, a phase 2b clinical trial","volume":"116","author":"Turner","year":"2021","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0077|cit77","unstructured":"Allakos corporate update https:\/\/investor.allakos.com\/static-files\/74ad659a-8f45-4448-b1fb-97b647be1952 2022"},{"issue":"Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.14309\/01.ajg.0000858424.48968.ad","article-title":"Results from KRYPTOS, a phase 2\/3 study of lirentelimab (AK002) in adults and adolescents with EoE","volume":"117","author":"Dellon","year":"2022","journal-title":"American journal of Gastroenterology"},{"issue":"8S","key":"10.1002\/14651858.CD004065.pub4-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/2050640620927344","article-title":"Effect of elemental nutrition added to four-food elimination in adult eosinophilic esophagitis patients: a randomized controlled trial","volume":"8","author":"De Rooij","year":"2020","journal-title":"United European Gastroenterology Journal"},{"issue":"7","key":"10.1002\/14651858.CD004065.pub4-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"e14291","DOI":"10.1111\/nmo.14291","article-title":"Effect of amino acid-based formula added to four-food elimination in adult eosinophilic esophagitis patients: a randomized clinical trial","volume":"34","author":"De Rooij","year":"2022","journal-title":"Neurogastroenterology & Motility"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0081|cit81","unstructured":"Effect of addition of elemental nutrition to an elimination diet on esophageal inflammation in adult eosinophilic esophagitis (EoE) patients: a randomized controlled trial http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=NTR6778"},{"issue":"7","key":"10.1002\/14651858.CD004065.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"e14291","DOI":"10.1111\/nmo.14291","article-title":"Effect of amino acid-based formula added to four-food elimination in adult eosinophilic esophagitis patients: a randomized clinical trial","volume":"34","author":"Rooij","year":"2022","journal-title":"Neurogastroenterology and Motility"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0083|cit83","first-page":"S62","article-title":"A randomized, double-blind, placebo-controlled study of oral viscous budesonide (OVB) in children with eosinophilic esophagitis (EoE)","volume":"138","author":"Dohil","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.gastro.2010.05.001","article-title":"Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial","volume":"139","author":"Dohil","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0085|cit85","unstructured":"Use of topical budesonide in the treatment of eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00638456"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1016\/S0016-5085%2811%2960956-6","article-title":"Reduction of esophageal epithelial pathology and endoscopic abnormalities following treatment with oral budesonide suspension (OBS) in pediatric subjects with eosinophilic esophagitis (EoE)","volume":"140","author":"Collins","year":"2011","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1016\/S0016-5085%2811%2960725-7","article-title":"Efficacy and safety of oral budesonide suspension (OBS) in pediatric subjects with eosinophilic esophagitis (EoE): results from the double-blind, placebo-controlled PEER study","volume":"140","author":"Gupta","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD004065.pub4-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cgh.2014.05.021","article-title":"Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis","volume":"13","author":"Gupta","year":"2015","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0089|cit89","unstructured":"Dose-ranging study of oral viscous budesonide in pediatrics with eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00762073"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0090|cit90","unstructured":"Effects of diet and omeprazole in patients with eosinophilic oesophagitis: a multi-centre, randomised controlled trial and investigation of novel disease mechanisms http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ACTRN12613001210763"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"AB309","DOI":"10.1016\/j.jaci.2018.12.940","article-title":"Effect of a 4-food elimination diet and omeprazole in children with eosinophilic esophagitis - a randomized controlled trial","volume":"143","author":"Heine","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"A124","DOI":"10.1177\/2050640618792817","article-title":"Long-term efficacy and safety of RPC4046, an anti-interleukin-13 monoclonal antibody, in patients with eosinophilic esophagitis: Results from the openlabel extension of the heroes study","volume":"6","author":"Dellon E","year":"2018","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl 106","key":"10.1002\/14651858.CD004065.pub4-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/all.13961","article-title":"Long-term efficacy and safety of RPC4046, an anti-interleukin-13 monoclonal antibody, in patients with eosinophilic esophagitis: results from the open-label extension of the heroes study","volume":"74","author":"Dellon E","year":"2019","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 106","key":"10.1002\/14651858.CD004065.pub4-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/all.13957","article-title":"Efficacy of RPC4046, an anti-interleukin-13 monoclonal antibody, in patients with active eosinophilic esophagitis: Analysis of the steroid-refractory subgroup from the heroes study","volume":"74","author":"Dellon E","year":"2019","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"AB208","DOI":"10.1016\/j.jaci.2018.12.635","article-title":"Long-term efficacy and safety of RPC4046, an anti-interleukin-13 monoclonal antibody, in patients with eosinophilic esophagitis: results from the open-label extension of the HEROES study","volume":"143","author":"Dellon","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"A51","DOI":"10.1177\/2050640618792817","article-title":"Efficacy of RPC4046, an anti-interleukin-13 monoclonal antibody, in patients with active eosinophilic esophagitis: Analysis of the steroidrefractory subgroup from the heroes study","volume":"6","author":"Dellon","year":"2018","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"S186","DOI":"10.1038\/ajg.2016.355","article-title":"A randomized, double-blind, placebo-controlled trial of a novel recombinant, humanized, anti-interleukin-13 monoclonal antibody (RPC4046) in patients with active eosinophilic esophagitis: Results of the heroes study","volume":"111 Suppl 1","author":"Dellon","year":"2016","journal-title":"American Journal of Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085%2818%2931195-8","article-title":"Efficacy and safety of rpc4046, an anti-interleukin-13 monoclonal antibody, in patients with active eosinophilic esophagitis: analysis of the steroid-refractory subgroup from the HEROES study","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1016\/S0016-5085(18)30996-X","article-title":"Sustained long-term efficacy and safety of rpc4046, an anti-interleukin-13 monoclonal antibody, in patients with eosinophilic esophagitis: results from the open-label extension of the HEROES study","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cgh.2020.03.036","article-title":"Long-term efficacy and tolerability of rpc4046 in an open-label extension trial of patients with eosinophilic esophagitis","volume":"19","author":"Dellon","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jaci.2020.03.045","article-title":"An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: phase 2 trial results","volume":"146","author":"Gann","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"A507","DOI":"10.1177\/2050640618792819","article-title":"Markers of esophageal epithelial mesenchymal transition are significantly reduced in active eosinophilic esophagitis following 16 weeks of treatment with RPC4046, an anti-interleukin-13 monoclonal antibody","volume":"6","author":"Gann","year":"2018","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl 106","key":"10.1002\/14651858.CD004065.pub4-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/all.13957","article-title":"Markers of esophageal epithelial-mesenchymal transition are significantly reduced in active EoE following 16 weeks of treatment with RPC4046, an anti-interleukin-13 monoclonal antibody","volume":"74","author":"Gann","year":"2019","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"AB135","DOI":"10.1016\/j.jaci.2018.12.409","article-title":"Markers of esophageal epithelial-mesenchymal transition are significantly reduced in active eosinophilic esophagitis following 16 weeks of treatment with RPC4046, an anti-interleukin-13 monoclonal antibody","volume":"143","author":"Gann","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"S243","DOI":"10.1016\/S0016-5085%2818%2931192-2","article-title":"Markers of esophageal epithelial-mesenchymal transition (emt) are significantly reduced in active eosinophilic esophagitis following 16 weeks of treatment with RPC4046, an anti-interleukin-13 monoclonal antibody","volume":"154","author":"Gann","year":"2018","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"A127","DOI":"10.1177\/2050640616663688","article-title":"A randomised, double-blind, placebo-controlled trial of a novel recombinant, humanised, antiinterleukin-13 monoclonal antibody (RPC4046) in patients with active eosinophilic oesophagitis: Results of the heroes study","volume":"4","author":"Hirano","year":"2016","journal-title":"United European Gastroenterology Journal"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.anai.2018.09.047","article-title":"A randomized, double-blind, placebo-controlled trial of anti-interleukin-13 monoclonal antibody RPC4046 in patients with eosinophilic esophagitis","volume":"121","author":"Hirano","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against il13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"AB308","DOI":"10.1016\/j.jaci.2018.12.939","article-title":"Efficacy of RPC4046, an anti-interleukin-13 monoclonal antibody, in patients with active eosinophilic esophagitis: analysis of the steroid-refractory subgroup from the HEROES study","volume":"143","author":"Hirano","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0110|cit110","unstructured":"Dose ranging study of RPC4046 in eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02098473"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"S259","DOI":"10.1016\/S0016-5085(18)31232-0","article-title":"Baseline characteristics and correlation between dysphagia and disease activity in patients with eosinophilic esophagitis in a randomized, placebo-controlled, phase 2 dupilumab trial","volume":"154","author":"Collins","year":"2018","journal-title":"Gastroenterology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/2050640620927344","article-title":"The gene expression signature modulated by dupilumab is highly correlated with eosinophilic esophagitis histological severity","volume":"8","author":"Collins","year":"2020","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl 109","key":"10.1002\/14651858.CD004065.pub4-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/all.14504","article-title":"Dupilumab suppresses serum total IgE levels across multiple atopic, allergic diseases","volume":"75","author":"Corren","year":"2020","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.1016\/S0016-5085%2818%2931193-4","article-title":"Endoscopic features are significantly associated with histologic measures of disease activity in patients with active eosinophilic esophagitis: a post HOC analysis of a randomized, placebo-controlled, phase 2 dupilumab trial","volume":"154","author":"Hirano","year":"2018","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD004065.pub4-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1177\/2397847317743186","article-title":"Dupilumab efficacy and safety in adult patients with active eosinophilic oesophagitis: a randomised double-blind placebo-controlled phase 2 trial","volume":"5","author":"Hirano","year":"2017","journal-title":"United European Gastroenterology Journal"},{"issue":"1","key":"10.1002\/14651858.CD004065.pub4-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.1016\/S0016-5085%2818%2931194-6","article-title":"Correlation between esophageal distensibility and objective measures of disease in patients with active eosinophilic esophagitis: a post hoc analysis of a randomized, placebo-controlled, phase 2 dupilumab trial","volume":"154","author":"Hirano","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0118|cit118","unstructured":"Study of dupilumab in adult participants with active eosinophilic esophagitis (EoE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02379052"},{"issue":"8","key":"10.1002\/14651858.CD004065.pub4-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/apt.15670","article-title":"Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis","volume":"51","author":"Hirano","year":"2020","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/S0016-5085(17)30960-5","article-title":"A randomized, double-blind, placebo-controlled trial of a fluticasone propionate orally disintegrating tablet in adult and adolescent patients with eosinophilic esophagitis: a phase 1\/2A safety and tolerability study","volume":"152","author":"Hirano","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0121|cit121","unstructured":"Safety and tolerability study of oral EUR-1100 to treat eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01386112"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"AB166","DOI":"10.1016\/j.jaci.2019.12.341","article-title":"Budesonide oral suspension improves histologic features in patients with eosinophilic esophagitis: results from a phase 3, randomized, double-blind, placebo-controlled trial","volume":"145","author":"Collins","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.14309\/01.ajg.0000703664.24718.78","article-title":"Improved histopathologic features in patients with eosinophilic esophagitis: results and analyses from a phase 3, randomized, placebo-controlled trial of budesonide oral suspension","volume":"115 Suppl","author":"Collins","year":"2020","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004065.pub4-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MPG.0000000000002518","article-title":"Study design and baseline patient characteristics of a phase 3, randomized, placebo-controlled trial of budesonide oral suspension in patients with eosinophilic esophagitis","volume":"69","author":"Dellon","year":"2019","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1016\/j.jval.2020.04.361","article-title":"PGI1 estimation of the minimal important differences in eosinophilic esophagitis quality of life (EoE-QoL): analysis from a phase 3, randomized, placebo-controlled trial of budesonide oral suspension","volume":"23","author":"Goodwin","year":"2020","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.jval.2020.04.390","article-title":"PGI36 Estimation of the minimal important differences in euroqol-5 dimensions (EQ-5D) for patients with eosinophilic esophagitis: analysis from a phase 3, randomized, placebo-controlled trial of budesonide oral suspension","volume":"23 Suppl 1","author":"Goodwin","year":"2020","journal-title":"Value in Health"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","article-title":"Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial","volume":"20","author":"Hirano","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","article-title":"Correction: Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial (Clinical Gastroenterology and Hepatology (2022) 20(3) (525-534.e10), (S1542356521004560), (10.1016\/j.cgh.2021.04.022))","volume":"20","author":"Hirano","year":"2022","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S0016-5085%2820%2930788-5","article-title":"227 Budesonide oral suspension (bos) improves endoscopic activity in adolescents and adults with eosinophilic esophagitis: results and correlation analysis from a phase 3, randomized, placebo-controlled trial","volume":"158","author":"Hirano","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD004065.pub4-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.anai.2019.08.338","article-title":"Budesonide oral suspension treatment improves dysphagia symptoms in patients with eosinophilic esophagitis","volume":"123","author":"Hirano","year":"2019","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.14309\/01.ajg.0000703788.60508.8e","article-title":"Determination of the eosinophilic esophagitis endoscopic reference score associated with histologic response to therapy: analysis from a phase 3 placebo-controlled trial of budesonide oral suspension","volume":"115 Suppl","author":"Hirano","year":"2020","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"S205","DOI":"10.14309\/01.ajg.0000590932.88962.0b","article-title":"Efficacy of budesonide oral suspension for eosinophilic esophagitis in adolescents and adults: Results from a phase 3, randomized, placebo-controlled trial","volume":"114 Suppl","author":"Hirano","year":"2019","journal-title":"American Journal of Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0016-5085(20)32723-2","article-title":"Predictors of response to corticosteroid therapy in patients with eosinophilic esophagitis: results from a phase 3, randomized, placebo-controlled trial of budesonide oral suspension","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0134|cit134","unstructured":"A placebo- controlled study in adolescents and adults with eosinophilic esophagitis (EoE) measuring histologic response and determine if reduction in dysphagia is achieved https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02605837"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0135|cit135","first-page":"S","article-title":"Efficacy of 1-food and 4-food elimination diets for pediatric eosinophilic esophagitis in a randomized multisite study","volume":"156","author":"Kliewer","year":"2019","journal-title":"Gastroenterology"},{"issue":"(6 Suppl)","key":"10.1002\/14651858.CD004065.pub4-BIB0136|cit136","first-page":"S","article-title":"Efficacy of one-food versus six-food elimination diet for treatment of eosinophilic esophagitis in adults: results from the multicenter randomized controlled sofeed trial","volume":"160","author":"Kliewer","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0137|cit137","unstructured":"Eosinophilic esophagitis intervention trial-1 food vs. 4 food elimination diet followed by swallowed glucocorticoids https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02610816"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/S0016-5085(19)37223-3","article-title":"535 Efficacy of one-food versus six-food elimination diet for treatment of eosinophilic esophagitis in adults: results from the multicenter randomized controlled sofeed trial","volume":"160","author":"Kliewer","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0139|cit139","unstructured":"SOFEED: Six food vs. one food eosinophilic esophagitis diet study https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02778867"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1053\/j.gastro.2006.08.033","article-title":"A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis","volume":"131","author":"Konikoff","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0141|cit141","unstructured":"A study comparing swallowed Flovent and placebo in patients with eosinophilic disorders https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00266578"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.anai.2018.03.006","article-title":"A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis","volume":"120","author":"Lieberman","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.anai.2017.08.054","article-title":"Viscous oral cromolyn for the treatment of eosinophilic esophagitis: a double-blind, placebo-controlled trial","volume":"119","author":"Lieberman","year":"2017","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0144|cit144","unstructured":"Oral cromolyn sodium for the treatment of eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02371941"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/S0016-5085(17)30997-6","article-title":"Budesonide orodispersible tablets are highly effective for treatment of active eosinophilic esophagitis: results from a randomized, double-blind, placebo-controlled, pivotal multicenter trial (EOS-1)","volume":"152","author":"Lucendo","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD004065.pub4-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","article-title":"Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial","volume":"157","author":"Lucendo","year":"2019","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"S715","DOI":"10.1016\/S0016-5085%2819%2938723-2","article-title":"Efficacy of budesonide orodispersible tablets for induction of remission in patients with active eosinophilic esophagitis: results from the 6-weeks open-label treatment phase of EOS-2 trial","volume":"156","author":"Schlag","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0148|cit148","unstructured":"A study to investigate the efficacy and tolerance of budesonide tablets and suspension in patients suffering from esophagitis over a 14 day period https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2009-016692-29-BE"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"A128","DOI":"10.1177\/2050640614548974","article-title":"A randomized, double-blind, double-dummy, placebo-controlled, European multicentre trial of two new budesonide formulations for treatment of active eosinophilic esophagitis","volume":"2","author":"Hruz","year":"2014","journal-title":"United European Gastroenterology Journal"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/gutjnl-2014-308815","article-title":"A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis","volume":"65","author":"Miehlke","year":"2016","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/S0016-5085%2814%2960055-X","article-title":"Two new budesonide formulations are highly efficient for treatment of active eosinophilic esophagitis: Results from a randomized, double-blind, double-dummy, placebo-controlled multicenter trial","volume":"146","author":"Miehlke","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0152|cit152","unstructured":"Budesonide effervescent tablets vs. viscous budesonide suspension vs. placebo in eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02280616"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.14309\/00000434-201110002-00030","article-title":"Comparison of aerosolized swallowed fluticasone to esomeprazole for the treatment of eosinophilic esophagitis","volume":"106","author":"Moawad","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/ajg.2012.443","article-title":"Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia","volume":"108","author":"Moawad","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0155|cit155","unstructured":"Fluticasone versus esomeprazole to treat eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00895817"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0156|cit156","first-page":"89","article-title":"A randomized controlled trial comparing six-food elimination diet vs topical steroids in inducing and maintaining remission of paediatric eosinophilic esophagitis","volume":"66 Suppl 2","author":"Oliva","year":"2018","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1016\/S0016-5085(18)30957-0","article-title":"A randomized controlled trial comparing six-food elimination diet vs topical steroids in inducing and maintaining remission of pediatric eosinophilic esophagitis","volume":"154","author":"Oliva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0158|cit158","unstructured":"Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00123656"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s10620-009-0859-4","article-title":"Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis","volume":"55","author":"Peterson","year":"2010","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0160|cit160","unstructured":"Efficacy and safety of QAX576 in patients with eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01022970"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"25","key":"10.1002\/14651858.CD004065.pub4-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"2 (Suppl)","key":"10.1002\/14651858.CD004065.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"AB312","DOI":"10.1016\/j.jaci.2021.12.003","article-title":"Dupilumab improves clinical and histologic aspects of disease in adult and adolescent patients with eosinophilic esophagitis at week 24: results from Part B of the 3-PartLIBERTY EoE TREET Study","volume":"149","author":"Rothenberg","year":"2022","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"A19","DOI":"10.1016\/S0016-5085(03)80096-3","article-title":"Treatment of allergic eosinophilic esophagitis (AEE) with oral prednisone (P) and swallowed fluticasone (F): a randomized, prospective study in children","volume":"124","author":"Gupta","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cgh.2007.11.008","article-title":"Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children","volume":"6","author":"Schaefer","year":"2008","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004065.pub4-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1097\/01.mpg.0000503536.79797.66","article-title":"Long-term safety and efficacy of reslizumab in children and adolescents with eosinophilic esophagitis: A review of 501 doses in 12 children over 8 years","volume":"63","author":"Markowitz","year":"2016","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0167|cit167","first-page":"AB234","article-title":"Long-term safety and efficacy of reslizumab in children and adolescents with eosinophilic esophagitis: a review of 477 doses in 12 children over 7 years","volume":"137","author":"Markowitz","year":"2016","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"6","key":"10.1002\/14651858.CD004065.pub4-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/MPG.0000000000001840","article-title":"Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated for 9 years","volume":"66","author":"Markowitz","year":"2018","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0169|cit169","unstructured":"Efficacy and safety study of reslizumab to treat eosinophilic esophagitis in subjects aged 5 to 18 years https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00538434"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/S0016-5085(11)60554-4","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled study","volume":"140","author":"Spergel","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/all.14659","article-title":"Sustained milk consumption after 2 years post-milk epicutaneous immunotherapy for eosinophilic esophagitis","volume":"76","author":"Burke","year":"2021","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0173|cit173","unstructured":"Milk patch for eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02579876 2015"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.cgh.2019.05.014","article-title":"Efficacy of epicutaneous immunotherapy in children with milk-induced eosinophilic esophagitis","volume":"18","author":"Spergel","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD004065.pub4-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jaci.2010.04.029","article-title":"Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis","volume":"126","author":"Conus","year":"2010","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0176|cit176","unstructured":"A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg\/kg, 2.5mg\/kg or 10mg\/kg) in pediatric subjects with eosinophilic esophagitis, ag https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2005-006074-10-GB"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0177|cit177","unstructured":"An evaluation of mepolizumab in therapy of eosinophilic oesophagitis in adult patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00274703"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jaci.2007.12.179","article-title":"Mepolizumab, a humanized monoclonal antibody to IL-5, for severe eosinophilic esophagitis in adults: a randomized, placebo-controlled double-blind trial","volume":"121","author":"Straumann","year":"2008","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD004065.pub4-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0180|cit180","unstructured":"Degen L Bussmann C Conus S Thalmann C Simon H Straumann A Budesonide as induction treatment for active eosinophilic esophagitis in adolescents and adults: a randomised, double-blind, placebo-controlled study (BEE-I trial) Allergy: European Journal of Allergy and Clinical Immunology 2010 343 4 10.1111\/j.1398-9995.2010.02393.x"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1053\/j.gastro.2010.07.048","article-title":"Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis","volume":"139","author":"Straumann","year":"2010","journal-title":"Gastroenterology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1016\/j.jaci.2008.12.1037","article-title":"Budesonide as induction treatment for active eosinophilic esophagitis in adolescents and adults: a randomized, double-blind, placebo-controlled Study","volume":"123","author":"Straumann","year":"2009","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0183|cit183","unstructured":"Budesonide for eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00271349"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1398-9995.2010.02393.x","article-title":"Maintenance-treatment of eosinophilic esophagitis with budesonide (BEE-M trial)","volume":"65 Suppl 92","author":"Straumann","year":"2010","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cgh.2011.01.017","article-title":"Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis","volume":"9","author":"Straumann","year":"2011","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0186|cit186","first-page":"S123","article-title":"Long-term treatment of eosinophilic esophagitis with budesonide","volume":"138","author":"Straumann","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0187|cit187","unstructured":"Proof of concept study of OC000459 in eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01056783"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"A123","DOI":"10.1177\/2050640613502899","article-title":"Treatment of eosinophilic esophagitis with the CRTH2-antagonist oc000459: a novel therapeutic principle","volume":"1","author":"Straumann","year":"2013","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0189|cit189","first-page":"8S","article-title":"Treatment of eosinophilic esophagitis with the CRTH2-antagonist OC000459: a novel therapeutic principle","volume":"142","author":"Straumann","year":"2012","journal-title":"Swiss Medical Weekly"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1016\/S0016-5085(12)60552-6","article-title":"Treatment of eosinophilic esophagitis with the crth2-antagonist oc000459: a novel therapeutic principle","volume":"142","author":"Straumann","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/all.12096","article-title":"Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis","volume":"68","author":"Straumann","year":"2013","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0192|cit192","first-page":"55","article-title":"A novel budesonide orodispersible tablet formulation is highly effective to maintain endoscopic inflammatory remission and even complete endoscopic remission in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placeb","volume":"7","author":"Biedermann","year":"2019","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0193|cit193","unstructured":"Double-blind (neither physician nor patient knows of the actual treatment which can with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (tested against tablets without active https:\/\/eudract.ema.europa.eu\/"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0194|cit194","unstructured":"Double-blind (neither physician nor patient knows of the actual treatment which can with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), phase III study on the efficacy and tolerability of a 48- https:\/\/eudract.ema.europa.eu\/"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0195|cit195","first-page":"S","article-title":"Budesonide orodispersible tablets are highly effective to maintain clinico-histological remission in adult patients with eosinophilic esophagitis: results from the 48-weeks, double-blind, placebo-controlled, pivotal eos-2 trial","volume":"156","author":"Lucendo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(18)30704-2","article-title":"Prolongation of eosinophilic esophagitis treatment with budesonide orodispersible tablets for incomplete responder is effective and safe: results from a 6-weeks open-label treatment phase of the pivotal trial EOS-1","volume":"154","author":"Lucendo","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0197|cit197","first-page":"54","article-title":"A novel oral budesonide formulation is highly effective for induction of remission in patients with active eosinophilic esophagitis: results from the 6-weeks open-label treatment phase of EOS-2 trial","volume":"7","author":"Lucendo","year":"2019","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0016-5085(19)38724-4","article-title":"Budesonide orodispersible tablets can effectively induce complete remission of endoscopic and histologic mucosal abnormalities and can induce deep disease remission in active eosinophilic esophagitis: results from a post-hoc analysis of the randomized, do","volume":"156","author":"Lucendo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0199|cit199","first-page":"78","article-title":"A randomized, double-blind, placebo controlled, pivotal multicenter trial with budesonide orodispersible tablets for treatment of active eosinophilic esophagitis (EOS-1)","volume":"72","author":"Miehlke","year":"2017","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0200|cit200","first-page":"37","article-title":"Predictive factors for early vs delayed response to budesonide orodispersible tablets in eosinophilic esophagitis: Results from the pivotal trial EOS-1","volume":"73","author":"Miehlke","year":"2018","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0201|cit201","first-page":"423","article-title":"A novel budesonide orodispersibletablet with a special esophageal-targeting can induce complete clinical, endoscopic and histologic remission in active Eosinophilic Esophagitis: results from a post-hoc analysis of the randomized, double-blind, placebo-controlled EOS-1 trial","volume":"7","author":"Miehlke","year":"2019","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0202|cit202","unstructured":"Budesonide orodispersible tablet vs. placebo in active eosinophilic esophagitis ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0203|cit203","first-page":"705","article-title":"Budesonide orodispersible tablets are superior to maintain and even further improve quality of life in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial","volume":"7","author":"Schlag","year":"2019","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"JC44","DOI":"10.7326\/ACPJ202104200-044","article-title":"In eosinophilic esophagitis, budesonide orodispersible tablets maintained remission at 48 wk","volume":"174","author":"Srinivasan","year":"2021","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0205|cit205","first-page":"10S","article-title":"Efficacy and safety of budesonide orodispersible tablets in active eosinophilic oesophagitis: Results from a randomised, double-blind, placebo-controlled, pivotal, European multicentre trial (EOS-1)","volume":"147","author":"Straumann","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2020.07.039","article-title":"Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis","volume":"159","author":"Straumann","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl 253","key":"10.1002\/14651858.CD004065.pub4-BIB0207|cit207","first-page":"2S","article-title":"Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis","volume":"151","author":"Straumann","year":"2021","journal-title":"Swiss Medical Weekly"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0208|cit208","first-page":"A146","article-title":"Efficacy and safety of budesonide orodispersible tablets in active eosinophilic oesophagitis: Results from a randomised, double blind, placebo-controlled, pivotal, European multicenre trial (EOS-1)","volume":"5","author":"Straumann","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0209|cit209","unstructured":"Treatment of patients with eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II study https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2012-005842-39-SE"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0210|cit210","unstructured":"Mometasone-furoate for treatment of eosinophilic esophagitis - a randomized placebo controlled study https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02113267"},{"issue":"6","key":"10.1002\/14651858.CD004065.pub4-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/00365521.2021.1906314","article-title":"Topically applied mometasone furoate improves dysphagia in adult eosinophilic esophagitis-results from a double-blind, randomized, placebo-controlled trial","volume":"56","author":"Tytor","year":"2021","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1398-9995.2006.01224.x","article-title":"Eosinophilic esophagitis in adults - no clinical relevance of wheat and rye sensitizations","volume":"61","author":"Braathen","year":"2006","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaci.2005.05.011","article-title":"Topical viscous budesonide suspension for treatment of eosinophilic esophagitis","volume":"116","author":"Aceves","year":"2005","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"A351","DOI":"10.1177\/2050640617725676","article-title":"A phase 1 study to assess the pharmacokinetics, safety, and tolerability of single dose APT-1011 administered under fed or fasted conditions or at bedtime in a randomised three-way, crossover design","volume":"5","author":"Comer","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0215|cit215","first-page":"23","article-title":"Different proton pump inhibitors are equally effective in inducing endoscopic and histologic remission in patients with proton pump inhibitor-response esophageal eosinophilia","volume":"29","author":"Della Coletta","year":"2017","journal-title":"Neurogastroenterology and Motility"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S1590-8658(18)30525-5","article-title":"Esomeprazole, rabeprazole and pantoprazole are equally effective in inducing endoscopic and histologic remission in patients with proton pump inhibitor-response esophageal eosinophilia","volume":"50","author":"Della Coletta","year":"2018","journal-title":"Digestive and Liver Disease"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0217|cit217","first-page":"A352","article-title":"Esomeprazole, rabeprazole and pantoprazole are equally effective in inducing endoscopic and histologic remission in patients with proton pump inhibitor-response esophageal eosinophilia","volume":"5","author":"Della Coletta","year":"2017","journal-title":"UEG Journal"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0218|cit218","first-page":"S860","article-title":"Different proton pump inhibitors are equally effective in inducing endoscopic and histologic remission in patients with proton pump inhibitor-response esophageal eosinophilia","volume":"152","author":"Della Coletta","year":"2017","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/S0016-5085(20)31149-5","article-title":"Histologic and symptomatic improvement across multiple forms of eosinophilic gastrointestinal diseases in enigma, a randomized, double-blind, placebo-controlled trial of antolimab (AK002)","volume":"158","author":"Dellon","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0220|cit220","unstructured":"A study of antolimab (AK002) in patients with active eosinophilic esophagitis ClinicalTrials.gov 2020"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"S858","DOI":"10.1016\/S0016-5085(17)32952-9","article-title":"Clinical and molecular predictors of histologic response to topical steroid treatment in eosinophilic esophagitis: Results from a prospective study","volume":"152","author":"Eluri","year":"2017","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"AB121","DOI":"10.1016\/j.gie.2017.03.199","article-title":"A multivariable model predicts complete histologic response to topical corticosteroid treatment in eosinophilic esophagitis","volume":"85","author":"Eluri","year":"2017","journal-title":"Gastrointestinal Endoscopy"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0223|cit223","unstructured":"Spontaneous study on the efficacy and safety of an oral viscous suspension of budesonide administered to children affected by eosinophilic esophagitis https:\/\/eudract.ema.europa.eu"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2036.2011.04922.x","article-title":"Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis","volume":"35","author":"Francis","year":"2012","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s10620-015-3990-4","article-title":"A randomized controlled comparison of esophageal clearance times of oral budesonide preparations","volume":"61","author":"Hefner","year":"2016","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/j.1572-0241.2008.01989.x","article-title":"3-yr-follow-up of topical corticosteroid treatment for eosinophilic esophagitis in adults","volume":"9","author":"Helou","year":"2008","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41687-017-0006-5","article-title":"Psychometric validation of the dysphagia symptom questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension","volume":"1","author":"Hudgens","year":"2017","journal-title":"Journal of Patient-reported Outcomes"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0228|cit228","unstructured":"A study investigating the therapeutic effect of vonoprazan on the patients with proton pump inhibitor resistant eosinophilic esophagitis https:\/\/trialsearch.who.int\/?TrialID=JPRN-UMIN000021041"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0229|cit229","unstructured":"A study investigating the effect of CYP2C19 polymorphism on the therapeutic efficacy in patients with eosinophilic esophagitis https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000030656"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.cgh.2006.05.026","article-title":"Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis","volume":"4","author":"Kagalwalla","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/dote.12398","article-title":"Randomized controlled trial comparing esophageal dilation to no dilation among adults with esophageal eosinophilia and dysphagia","volume":"29","author":"Kavitt","year":"2016","journal-title":"Diseases of the Esophagus"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/dote.12339","article-title":"Prospective, comparative effectiveness trial of cow's milk elimination and swallowed fluticasone for pediatric eosinophilic esophagitis","volume":"29","author":"Kruszewski","year":"2016","journal-title":"Diseases of the Esophagus"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s10388-020-00783-0","article-title":"Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis","volume":"18","author":"Kuzumoto","year":"2021","journal-title":"Esophagus"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/S0016-5085(17)30998-8","article-title":"Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study","volume":"152","author":"Molina-Infante","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0235|cit235","unstructured":"A trial of montelukast for maintenance therapy of eosinophilic esophagitis in children https:\/\/ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0236|cit236","unstructured":"A six month, safety follow-up study in eosinophilic esophagitis subjects who completed study PR-021 https:\/\/ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0237|cit237","unstructured":"Eosinophilic esophagitis treatment: montelukast vs fluticasone https:\/\/ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0238|cit238","unstructured":"Eosinophilic esophagitis clinical therapy comparison trial https:\/\/ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0239|cit239","unstructured":"Effect of amino acid formula on esophageal inflammation and intestinal permeability in adult eosinophilic esophagitis patients https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NTR4892"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/apt.13370","article-title":"Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity","volume":"42","author":"Safroneeva","year":"2015","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0241|cit241","first-page":"S256","article-title":"Short- and long-term therapeutic goals of adult patients with eosinophilic esophagitis","volume":"154","author":"Safroneeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0016-5085(18)30708-X","article-title":"Both fibrotic and inflammatory endoscopic alterations contribute to symptom severity in adults with eosinophilic esophagitis","volume":"154","author":"Safroneeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"S415","DOI":"10.1016\/S0016-5085(15)31396-2","article-title":"Clinical and high resolution manometry data support the hypothesis that proton pump inhibitor-responsive esophageal eosinophilia represent a GERD-related phenomenon","volume":"148","author":"Savarino","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40268-020-00324-1","article-title":"A pharmacokinetic bridging study to compare systemic exposure to budesonide between budesonide oral suspension and entocort ec in healthy individuals","volume":"20","author":"Song","year":"2020","journal-title":"Drugs in R and D"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1067\/mai.2002.121458","article-title":"The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis","volume":"109","author":"Spergel","year":"2002","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1081-1206(10)61151-9","article-title":"Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests","volume":"95","author":"Spergel","year":"2005","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0247|cit247","first-page":"1107","article-title":"Oral viscous mometasone is an effective treatment for eosinophilic esophagitis","volume":"8","author":"Syverson","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"6","key":"10.1002\/14651858.CD004065.pub4-BIB0248|cit248","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s12325-017-0525-8","article-title":"RPC4046, a novel anti-interleukin-13 antibody, blocks IL-13 binding to IL-13 alpha 1 and alpha 2 receptors: a randomized, double-blind, placebo-controlled, dose-escalation first-in-human study","volume":"34","author":"Tripp","year":"2017","journal-title":"Advances in Therapy"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004065.pub4-BIB0249|cit249","first-page":"A104","article-title":"The characterization of RPC4046, a novel anti-IL13 monoclonal antibody that blocks binding to IL-13 receptor alpha1 and alpha 2 in development for eosinophilic esophagitis: Results of a first-inhuman study","volume":"113","author":"Tripp","year":"2014","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/apt.12513","article-title":"The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor","volume":"38","author":"Vazquez-Elizondo","year":"2013","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0251|cit251","first-page":"S864","article-title":"Assessing adherence and barriers to long term dietary elimination therapy in patients with eosinophilic esophagitis (EoE)","volume":"152","author":"Wang","year":"2017","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s10620-018-5045-0","article-title":"Assessing adherence and barriers to long-term elimination diet therapy in adults with eosinophilic esophagitis","volume":"63","author":"Wang","year":"2018","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0253|cit253","first-page":"S18","article-title":"Amino acid-based diet restores the esophageal mucosal integrity in eosinophilic esophagitis whereas duodenal mucosal integrity remains unaffected","volume":"150","author":"Warners","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.cgh.2017.05.048","article-title":"Efficacy of a 4-food elimination diet for children with eosinophilic esophagitis","volume":"15","author":"Wechsler","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"AB84","DOI":"10.1016\/j.jaci.2019.12.036","article-title":"Peanut oral immunotherapy induces gastrointestinal eosinophilia in a longitudinal randomized controlled trial","volume":"145","author":"Wright","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cgh.2020.05.019","article-title":"Gastrointestinal eosinophil responses in a longitudinal, randomized trial of peanut oral immunotherapy","volume":"19","author":"Wright","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"4211626","DOI":"10.1155\/2022\/4211626","article-title":"The effectiveness of synbiotic on the improvement of clinical symptoms in children with eosinophilic esophagitis","volume":"2022","author":"Amini","year":"2022","journal-title":"International Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0258|cit258","unstructured":"Dietetic versus topical steroids for pediatric eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01846962 2012 (first received 6 May 2013)"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0259|cit259","unstructured":"Two food group elimination diet versus swallowed fluticasone for the management of adult eosinophilic esophagitis, a single-centred randomised prospective study https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12619000141145"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0260|cit260","unstructured":"Efficacy of Fucoidan for eosinophilic oesophagitis: a phase 2 pilot study https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12621001406897"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0261|cit261","unstructured":"A phase III clinical study in adult and adolescent patients with eosinophilic inflammation of the gullet to prove superiority compared to placebo of an episodic and\/or a continuous 48-week treatment with budesonide orodispersible tablets for maintaining remission https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-003516-39\/DE"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0262|cit262","unstructured":"A phase III clinical study in adult and adolescent patients with eosinophilic inflammation of the gullet to prove superiority compared to placebo of an episodic and\/or a continuous 48-week treatment with budesonide orodispersible tablets for maintaining remission https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-003516-39\/ES"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0263|cit263","unstructured":"Double-blind (neither physician nor patient knows of the actual treatment which can be with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (one of the treatment groups receiv https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-003737-29\/DE"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0264|cit264","unstructured":"Double-blind (neither physician nor patient knows of the actual treatment which can be with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (one of the treatment groups receiv https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-003737-29\/ES 2019"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0265|cit265","unstructured":"A study of benralizumab in patients with eosinophilic esophagitis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-002871-32\/ES"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0266|cit266","unstructured":"A study of benralizumab in patients with eosinophilic esophagitis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-002871-32\/NL"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0267|cit267","unstructured":"Study to evaluate the efficacy and safety of AK002 in patients with active eosinophilic esophagitis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004391-19\/NL"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0268|cit268","unstructured":"A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagus https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000082-16\/DE"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0269|cit269","unstructured":"A study to investigate the efficacy and tolerability of ESO-101 in patients With eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04849390"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0270|cit270","unstructured":"clinical study to show equal clinical efficacy of two dosing regimen of budesonid orodispersible tablets (twice daily vs. once daily) for treatment of inflammation of the esophagus https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001314-37\/DE"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0271|cit271","unstructured":"A study evaluating the efficacy and safety of etrasimod in the treatment of patients with eosinophilic esophagitis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-003226-23\/BE"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0272|cit272","unstructured":"A study to assess the safety and efficacy of oral etrasimod in adult participants with eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04682639"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0273|cit273","unstructured":"A study to evaluate the efficacy and safety of CC-93538 in adult and adolescent patients who have eosinophilic esophagitis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004336-16\/DE"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0274|cit274","unstructured":"A study to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants With eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04753697"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004065.pub4-BIB0275|cit275","first-page":"195","article-title":"A novel food additive removal diet for eosinophilic esophagitis (free study): conceptual design and clinical trial methods","volume":"69","author":"Henry","year":"2019","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0276|cit276","unstructured":"evaluation of efficacy of synbiotics in children with eosinophilic esophagitis https:\/\/en.irct.ir\/search\/result?query=IRCT20171230038142N14"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0277|cit277","unstructured":"Comparison of the efficay and side effects of nebulized oral pulmicort and inhaler budesonide in patients with eosinophilic esophagitis https:\/\/en.irct.ir\/search\/result?query=IRCT20191211045703N1"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0278|cit278","unstructured":"A phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC-93538 in adult and adolescent subjects with eosinophilic esophagitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2051200140"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0279|cit279","unstructured":"Efficacy and safety of three doses of florence oral suspension in adults with eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02873468"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0280|cit280","unstructured":"Mepo for EoE study https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03656380"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0281|cit281","unstructured":"A food additive removal diet for pediatric eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03657771"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0282|cit282","unstructured":"EoE RCT fluticasone and omeprazole vs fluticasone alone https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03781596"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0283|cit283","unstructured":"Antihistamines in eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04248712"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0284|cit284","unstructured":"Study with eosinophilic esophagitis subjects https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001521-27\/DE"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0285|cit285","unstructured":"Efficacy and safety APT-1011 in adult subjects with eosinophilic esophagitis (EoE) (FLUTE-2) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04281108"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0286|cit286","unstructured":"Efficacy and safety APT-1011 in adolescent subjects with eosinophilic esophagitis (EoE) - a sub-study of the FLUTE-2 Trial https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05083312"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0287|cit287","unstructured":"Study to investigate the efficacy and safety of dupilumab in pediatric patients with active eosinophilic esophagitis (EoE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04394351"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0288|cit288","unstructured":"A study of benralizumab in patients with eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04543409 2020"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0289|cit289","unstructured":"Dose escalation study to evaluate an experimental new treatment (CALY-002) in healthy subjects and subjects with celiac disease and eosinophilic esophagitis https:\/\/ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0290|cit290","unstructured":"Safety and pharmacokinetics of orodispersible BT-11 in active eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04835168"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0291|cit291","unstructured":"A study to assess the efficacy, safety and tolerability of IRL201104 in adults with active eosinophilic esophagitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05084963"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0292|cit292","unstructured":"Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE) https:\/\/ClinicalTrials.gov\/show\/NCT05214599"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0293|cit293","unstructured":"The Immune Directed Individualized Elimination Therapy (iDIET) Study https:\/\/ClinicalTrials.gov\/show\/NCT05543512"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0294|cit294","unstructured":"Efficacy and safety of tezepelumab in patients with eosinophilic esophagitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2022-001294-31-DK 2022"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0295|cit295","unstructured":"Efficacy and safety of tezepelumab in patients with eosinophilic esophagitis https:\/\/ClinicalTrials.gov\/show\/NCT05583227"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0296|cit296","unstructured":"24- week induction study of APT-1011 in adult subjects with eosinophilic esophagitis (EoE) (FLUTE 3) https:\/\/ClinicalTrials.gov\/show\/NCT05634746"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0297|cit297","unstructured":"Targeted elimination diet in EoE patients following identification of trigger nutrients using confocal laser endomicroscopy https:\/\/ClinicalTrials.gov\/show\/NCT05695456"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000100511","article-title":"Diagnostic value of the Reflux Disease Questionnaire in general practice","volume":"74","author":"Aanen","year":"2006","journal-title":"Digestion"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0299|cit299","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1081-1206(10)60359-6","article-title":"A symptom scoring tool identifies pediatric eosinophilic esophagitis patients and correlates with tissue inflammation","volume":"103","author":"Aceves","year":"2009","journal-title":"Annals of Allergy Asthma and Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0300|cit300","first-page":"1","article-title":"Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring","volume":"30","author":"Collins","year":"2017","journal-title":"Diseases of the Esophagus"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0301|cit301","unstructured":"Covidence Veritas Health Innovation 2022"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1067\/S0016-5107(03)01870-4","article-title":"Clinical and endoscopic features of eosinophilic esophagitis in adults","volume":"58","author":"Croese","year":"2003","journal-title":"Gastrointestinal Endoscopy"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0303|cit303","first-page":"99","article-title":"A new dysphagia score with objective validation","volume":"14","author":"Dakkak","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0304|cit304","unstructured":"Deeks JJ Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD004065.pub4-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0306|cit306","first-page":"1459","article-title":"British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults","volume":"71","author":"Dhar","year":"2022","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0016-5107(02)70185-5","article-title":"Incision of recurrent distal esophageal (Schatzki) ring after dilation","volume":"56","author":"DiSario","year":"2002","journal-title":"Gastrointestinal Endoscopy"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.gtc.2020.04.002","article-title":"EndoFLIP in the esophagus: assessing sphincter function, wall stiffness, and motility to guide treatment","volume":"49","author":"Donnan","year":"2020","journal-title":"Gastroenterology Clinics of North America"},{"issue":"7109","key":"10.1002\/14651858.CD004065.pub4-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD004065.pub4-BIB0310|cit310","first-page":"90","article-title":"Treatment of eosinophilic esophagitis with inhaled corticosteroids","volume":"27","author":"Perrault","year":"1998","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"12","key":"10.1002\/14651858.CD004065.pub4-BIB0311|cit311","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1185\/03007990802536900","article-title":"Patient and caregiver perspective on pediatric eosinophilic esophagitis and newly developed symptom questionnaires","volume":"24","author":"Flood","year":"2008","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0312|cit312","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1471-230X-11-126","article-title":"Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods","volume":"11","author":"Franciosi","year":"2011","journal-title":"BMC Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD004065.pub4-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MPG.0b013e31828f1fd2","article-title":"PedsQL\u2122 Eosinophilic Esophagitis Module: feasibility, reliability and validity","volume":"57","author":"Franciosi","year":"2013","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/JAA.S274524","article-title":"Proton pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions","volume":"15","author":"Franciosi","year":"2022","journal-title":"Journal of Asthma and Allergy"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1053\/j.gastro.2007.08.017","article-title":"First International Gastrointestinal Eosinophil Research Symposium (FIGERS)","volume":"133","author":"Furuta","year":"2007","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1002\/14651858.CD004065.pub4-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1056\/NEJMra1502863","article-title":"Eosinophilic esophagitis","volume":"373","author":"Furuta","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.3748\/wjg.v27.i43.7572","article-title":"Minimum sample size estimates for trials in inflammatory bowel disease: a systematic review of a support resource","volume":"27","author":"Gordon","year":"2021","journal-title":"World Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD004065.pub4-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/ajg.2017.202","article-title":"Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a therapeutic concept","volume":"112","author":"Greuter","year":"2017","journal-title":"Official Journal of the American College of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0319|cit319","first-page":"321","article-title":"Macroscopic versus microscopic diagnosis of reflux esophagitis: erosions or eosinophils?","volume":"22","author":"Hassall","year":"1996","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0320|cit320","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0321|cit321","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0322|cit322","unstructured":"Higgins JPT Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD004065.pub4-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/gutjnl-2011-301817","article-title":"Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system","volume":"62","author":"Hirano","year":"2013","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0324|cit324","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-017-0006-5","article-title":"Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension","volume":"1","author":"Hudgens","year":"2017","journal-title":"Journal of Patient-Reported Outcomes"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2050640620967899","article-title":"Sample-size estimation is not reported in 24% of randomised controlled trials of inflammatory bowel disease: a systematic review","volume":"9","author":"Iheozor-Ejiofor","year":"2021","journal-title":"United European Gastroenterology Journal"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0016-5085(95)90637-1","article-title":"Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula","volume":"109","author":"Kelly","year":"1995","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD004065.pub4-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1023\/A:1021769928180","article-title":"Eosinophilic Esophagitis: Strictures, Impaction, Dysphagia","volume":"48","author":"Khan","year":"2003","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0328|cit328","doi-asserted-by":"publisher","first-page":"698\u2013702","DOI":"10.1007\/978-94-007-0753-5_324","volume-title":"Encyclopedia of Quality of Life and Well-Being Research","author":"Landgraf","year":"2014"},{"issue":"4","key":"10.1002\/14651858.CD004065.pub4-BIB0329|cit329","first-page":"380","article-title":"Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids","volume":"26","author":"Liacouras","year":"1998","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD004065.pub4-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2011.02.040","article-title":"Eosinophilic esophagitis: updated consensus recommendations for children and adults","volume":"128","author":"Liacouras","year":"2011","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2050640616689525","article-title":"Guidelines on eosinophilic esophagitis:evidence-based statements and recommendations for diagnosis and management in children and adults","volume":"5","author":"Lucendo","year":"2017","journal-title":"UEG Journal"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.gie.2022.01.014","article-title":"Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis","volume":"95","author":"Ma","year":"2022","journal-title":"Gastrointestinal Endoscopy"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jaci.2021.07.001","article-title":"Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)","volume":"149","author":"Ma","year":"2022","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD004065.pub4-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1572-0241.2003.07390.x","article-title":"Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents","volume":"98","author":"Markowitz","year":"2003","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0335|cit335","first-page":"221\u201330","article-title":"The Mayo Dysphagia Questionnaire-30: documentation of reliability and validity of a tool for interventional trials in adults with esophageal disease","volume":"25","author":"McElhiney","year":"2009","journal-title":"Dysphagia"},{"issue":"13","key":"10.1002\/14651858.CD004065.pub4-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jama.2021.14920","article-title":"Eosinophilic esophagitis: a review","volume":"326","author":"Muir","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0337|cit337","first-page":"S1081","article-title":"Current state of biologics in treating eosinophilic esophagitis","volume":"22","author":"Nhu","year":"2022","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"6","key":"10.1002\/14651858.CD004065.pub4-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/j.1572-0241.2000.02073.x","article-title":"The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children","volume":"95","author":"Orenstein","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"s418","DOI":"10.14309\/00000434-200609001-01063","article-title":"Mayo Dysphagia Questionnaire \u20132 week: validation of a symptom questionnaire","volume":"101","author":"Peloquin","year":"2006","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MPG.0b013e31817f0197","article-title":"Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis","volume":"48","author":"Pentiuk","year":"2009","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.anai.2020.03.021","article-title":"Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters","volume":"124","author":"Rank","year":"2020","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"2","key":"10.1002\/14651858.CD004065.pub4-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cgh.2017.09.046","article-title":"Optimal histologic cutpoints for treatment response in patients with eosinophilic esophagitis: analysis of data from a prospective cohort study","volume":"16","author":"Reed","year":"2018","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0344|cit344","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1053\/j.gastro.2015.02.002","article-title":"Molecular, genetic, and cellular bases for treating eosinophilic esophagitis","volume":"148","author":"Rothenberg","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD004065.pub4-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"1230\u20136","DOI":"10.1053\/j.gastro.2013.08.015","article-title":"Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner","volume":"145","author":"Schoepfer","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD004065.pub4-BIB0347|cit347","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1053\/j.gastro.2014.08.028","article-title":"Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis","volume":"147","author":"Schoepfer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0348|cit348","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD004065.pub4-BIB0349|cit349","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1053\/j.gastro.2003.09.024","article-title":"Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years","volume":"125","author":"Straumann","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004065.pub4-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2010.07.048","article-title":"Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis","volume":"139","author":"Straumann","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/all.12096","article-title":"Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis","volume":"68","author":"Straumann","year":"2013","journal-title":"Allergy"},{"issue":"7","key":"10.1002\/14651858.CD004065.pub4-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2036.2011.04791.x","article-title":"The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life","volume":"34","author":"Taft","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD004065.pub4-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1053\/gast.2002.32998","article-title":"Eosinophilic oesophagitis in children: immunopathological analysis and response to fluticasone proprionate","volume":"122","author":"Teitelbaum","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD004065.pub4-BIB0354|cit354","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004065.pub3","article-title":"Non-surgical interventions for eosinophilic esophagitis","author":"Elliott","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T09:35:57Z","timestamp":1729848957000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004065.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Gut Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":354,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004065.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]}}}